Weight-loss drug Ozempic to debut in India soon

Weight-loss drug Ozempic to debut in India soon

Danish drug maker Novo Nordisk is set to launch in India Ozempic (semaglutide), its trailblazing once-a-week injectable brand that was originally approved to manage type 2 diabetes but found unprecedented demand for its significant benefits in patients with obesity or weight management issues. Approved first by the US FDA in 2017, Ozempic saw its global…

Read More
Trump’s 100% tariff on pharma will not impact generic makers, says Indian Pharma Alliance

Trump’s 100% tariff on pharma will not impact generic makers, says Indian Pharma Alliance

Indian Pharmaceutical Alliance (IPA) on Friday said US President Donald Trump’s move to impose 100 per cent import tariffs on pharmaceutical drugs from October 1 will impact only patented and branded products, not generic medicines. Reacting to the development, IPA Secretary General Sudarshan Jain said in a statement, “It is not applicable to generics medicines.”…

Read More
Zydus Saroglitazar shows positive Phase 3 results in rare liver disease PBC, US filing planned in 2026

Zydus Saroglitazar shows positive Phase 3 results in rare liver disease PBC, US filing planned in 2026

Zydus Therapeutics, the US-based innovation-focused specialty arm of Zydus Lifesciences, has announced promising results from a late-stage clinical trial of its experimental drug Saroglitazar. The drug is being tested for Primary Biliary Cholangitis (PBC) – a rare and progressive autoimmune liver disease which gradually destroys the bile ducts. The company plans to submit a US…

Read More